Zhongchao
Zhongchao's revenue fell 28.3% to $11 million in fiscal 2025. Its operating margin was −54.4%, down from −2.1% a year earlier. Free cash flow was $1 million. The diluted share count rose 425.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
Income statement
From fiscal 2017 to 2021, earnings per share fell 40.7% a year and net income 39.6% a year, as new shares raised the share count by 50% and diluted each share's earnings. Zhongchao then lost money in fiscal 2022, 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 14 | 12 | 13 | 13 | 14 |
| Debt incl. finance leases | 3 | 2 | — | — | — |
| Net debt (negative means net cash) | −12 | −10 | — | — | — |
| Net debt to EBITDA | −553.5x | — | — | — | — |
| Debt to equity | 0.1x | 0.1x | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 7.6x | 5.5x | 7.0x | 12.2x | 11.1x |
| Quick ratio | 7.6x | 5.4x | 6.8x | 11.8x | — |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 33.3% | −46.9% | −22.2% |
| Altman Z'' | 6.22 | 17.89 | 15.87 |
| Accruals ratio | −36.1% | 3.3% | −28.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Fail | Pass |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | — | — | — |
Compare
Put Zhongchao side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Zhongchao | FY25 | −28.3% | −54.4% | 6.1% | — | — | — | |
| Healthcare Triangle | FY25 | 18.8% | −70.5% | −119.0% | — | — | — | Compare |
| SOPHiA GENETICS | FY25 | 18.6% | −91.8% | −47.2% | −207.1% | — | 2 | Compare |
| OptimizeRx | FY25 | 18.8% | 10.7% | 17.1% | 6.4% | 0.2x | 8 | Compare |
| Firefly Neuroscience | FY25 | 957.4% | −775.5% | — | −411.7% | — | 4 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 10 | 13 | 15 | 18 | 16 | 14 | 19 | 16 | 11 |
| Revenue growth | — | 31.1% | 15.7% | 20.9% | −9.4% | −13.2% | 37.3% | −18.4% | −28.3% |
| Gross profit | 6 | 8 | 10 | 12 | 9 | 6 | 8 | 9 | 5 |
| Research and development | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Operating income | — | — | 4 | 4 | −0 | −3 | −13 | −0 | −6 |
| Net income | 2 | 3 | 4 | 4 | 0 | −3 | −11 | −1 | −6 |
| Diluted EPS (US$) | 6.24 | 11.60 | 14.96 | 14.64 | 0.77 | −9.04 | −34.83 | −0.99 | −1.85 |
| Diluted shares (millions) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Cash flow | |||||||||
| Cash from operations | −0 | 1 | 1 | −1 | 3 | −1 | 0 | −2 | 1 |
| Capital expenditure | 0 | 1 | 1 | 0 | 2 | 2 | 1 | 3 | 0 |
| Free cash flow | −1 | 1 | 0 | −1 | 1 | −2 | −1 | −5 | 1 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | — | — | 0 | 0 | 0 | 0 | 0 | 4 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 3 | 9 | — | 17 | 14 | 12 | 13 | 13 | 14 |
| Debt incl. finance leases | — | — | — | — | 3 | 2 | — | — | — |
| Total assets | — | 14 | 18 | 35 | 36 | 39 | 24 | 26 | 24 |
| Total liabilities | — | 3 | 2 | 3 | 4 | 6 | 3 | 2 | 2 |
| Shareholders' equity | 5 | 11 | 15 | 32 | 33 | 30 | 18 | 21 | 19 |
| Margins and ratios | |||||||||
| Gross margin | 59.6% | 65.4% | 68.7% | 66.0% | 57.9% | 44.9% | 43.8% | 56.2% | 45.0% |
| Operating margin | — | — | 24.5% | 25.0% | −2.0% | −20.9% | −68.3% | −2.1% | −54.4% |
| Net margin | 15.6% | 23.5% | 27.2% | 24.8% | 1.5% | −20.8% | −58.3% | −4.0% | −55.5% |
| Free cash flow margin | −5.8% | 5.0% | 0.6% | −6.7% | 6.5% | −16.1% | −4.0% | −28.5% | 6.1% |
| Rule of 40 (growth + FCF margin) | — | 36.1% | 16.3% | 14.2% | −2.9% | −29.3% | 33.3% | −46.9% | −22.2% |
| Return on capital | — | — | — | — | — | −10.7% | — | — | — |
| Return on equity | — | — | 30.3% | 18.9% | 0.7% | −9.4% | −47.3% | −3.3% | −32.0% |
| Return on assets | — | — | 25.5% | 17.0% | 0.7% | −7.8% | −36.0% | −2.6% | −25.2% |
| Net debt to EBITDA | — | — | — | — | −553.5x | — | — | — | — |